PharmaFrontiers(TM)
                                  Corporation
                                [Graphic Omitted]

          PHARMAFRONTIERS COMPLETES ACQUISITION OF MULTIPLE SCLEROSIS
               CELL THERAPY DEVELOPER OPEXA PHARMACEUTICALS, INC.

HOUSTON, November 8, 2004 - Cell therapy developer PharmaFrontiers Corporation
(OTCBB:PFTR.OB) has closed its previously announced acquisition of Opexa
Pharmaceuticals, Inc., a Houston-based developer of cell-based therapeutics for
autoimmune diseases, initially targeting multiple sclerosis (MS).

     In the all-stock transaction, Opexa shareholders received 2.5 million
shares, or approximately 25 percent of PharmaFrontiers' 9,866,838 outstanding
shares. PharmaFrontiers was advised in the transaction by Sanders Morris Harris
Group Inc.

     Opexa's Tovaxin(TM) T-cell therapy is in FDA Phase I/II human dose ranging
clinical trials to evaluate its safety and effectiveness in treating MS. Its
novel approach to MS therapy is expected to receive "fast track" status from the
U.S. Food and Drug Administration.

     "As a wholly owned subsidiary of PharmaFrontiers, Opexa will expand our
cell therapy technology base and bring in key scientific personnel and existing
research that is strongly complementary with PharmaFrontiers' adult stem cell
tissue regeneration development program," said PharmaFrontiers CEO David
McWilliams. "We believe that stem cell-initiated regeneration of the tissue
sheath around nerve fibers bears serious investigation as a logical and
potentially effective follow-on to a therapy that stops the nervous system
destruction of MS," he added.

     Opexa's patented and proprietary technologies are the result of research
conducted at Baylor College of Medicine. The approach enables the development of
individualized cell therapies that produce an immune response against myelin
reactive "pathogenic" T-cells. These T-cells are involved in the cause of MS,
facilitating attacks on the myelin insulation that protects nerve fibers in the
body's central nervous system. Tovaxin(TM) targets the specific self-reactive
T-cell receptor with the goal of avoiding the deleterious side effects of
current MS therapies. As a subcutaneously delivered cell therapy, Tovaxin(TM)
also potentially offers a competitive therapeutic advantage over the currently
available protein-based palliative therapeutics to MS. Opexa is also developing
applications of its technology in the diagnosis of MS.



                                      -2-


     PharmaFrontiers' strategy is to develop and commercialize cell therapies to
treat several major disease areas such as cardiac and pancreatic conditions.
The company holds the exclusive worldwide license from the U.S. Department of
Energy's Argonne National Laboratory for the use of adult pluripotent stem cells
derived from patients' own circulating blood.

     This press release contains forward-looking statements about
PharmaFrontiers within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, and pursuant to the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995.  For example, statements in the future tense, words such as "anticipates",
"estimates", "expects", "intends", "plans", "believes", and words and terms of
similar substance used in connection with any discussion of future results,
performance or achievements identify such forward-looking statements.  Those
forward-looking statements involve risks and uncertainties and are not
guarantees of future results, performance or achievements, and actual results,
performance or achievements could differ materially from the Company's current
expectations as a result of numerous factors, including those risks more fully
disclosed in the Company's filings with the U.S. Securities and Exchange
Commission, including the Company's Report on Form 8-K dated June 4, 2004.  The
Company undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may arise after the
date of this release.

                                  #   #   #

KEYWORDS:   Health & Medical, Finance, Stem Cells, Houston, Texas
COMPANIES:  PharmaFrontiers Corporation (OTCBB:PFTR.OB)